title: Regulation of renal 12(S)-hydroxyeicosatetraenoic acid in diabetes by angiotensin AT1 and AT2 receptors.
abstract: Diabetes is associated with increased production of 12(S)-hydroxyeicosatetraenoic acid [12(S)-HETE]. The mechanisms involved in this process remain unclear. We hypothesized that hyperglycemia and angiotensin II (ANG II) regulate renal 12(S)-HETE production via a balance between angiotensin AT(1) and AT(2) receptors activities. Using a microdialysis technique, renal interstitial fluid (RIF) levels of ANG II and 12(S)-HETE were monitored in normal control and streptozotocin-induced diabetic rats at baseline and then weekly thereafter for 12 wk. In a second group of normal and diabetic rats, 3 wk after development of diabetes, we monitored RIF 12(S)-HETE levels in response to acute AT(1) receptor blockade with valsartan or AT(2) receptor blockade with PD123319 individually or combined. Two weeks after induction of diabetes there was a 404% increase in ANG II (P < 0.05), a 149% increase in 12S-HETE (P < 0.05), and a 649% increase in urinary albumin excretion (P < 0.05). These levels remained elevated throughout the study. PD123319 given alone had no effect on 12(S)-HETE. Valsartan decreased 12(S)-HETE by 61.6% (P < 0.0001), a response that was abrogated when PD123319 was given with valsartan. These data demonstrate that hyperglycemia increases renal ANG II and 12(S)-HETE levels. The increase in 12(S)-HETE is mediated via AT(1) receptor. The attenuation of the effects of AT(1) receptor blockade by PD123319 suggests that AT(2) receptor contributes to the downregulation of renal 12(S)-HETE production.
authors.affiliation: Department of Medicine, University of Virginia School of Medicine, Charlottesville, Virginia 22908-1409, USA.
authors.forename: Emaad M
authors.initials: EM
authors.lastname: Abdel-Rahman
authors.forename: Peter M
authors.initials: PM
authors.lastname: Abadir
authors.forename: Helmy M
authors.initials: HM
authors.lastname: Siragy
mesh_terms: D019377:12-Hydroxy-5,8,10,14-eicosatetraenoic Acid / Q000378:metabolism*; D000804:Angiotensin II / Q000378:metabolism; D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology; D057912:Angiotensin II Type 2 Receptor Blockers; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism*; D003928:Diabetic Nephropathies / Q000378:metabolism*; D007004:Hypoglycemic Agents / Q000494:pharmacology; D007093:Imidazoles / Q000494:pharmacology; D066298:In Vitro Techniques; D007328:Insulin / Q000494:pharmacology; D007668:Kidney / Q000378:metabolism*; D008297:Male; D017551:Microdialysis; D011725:Pyridines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D044140:Receptor, Angiotensin, Type 1 / Q000378:metabolism*; D044139:Receptor, Angiotensin, Type 2 / Q000378:metabolism*; D013777:Tetrazoles / Q000494:pharmacology; D014633:Valine / Q000031:analogs & derivatives / Q000494:pharmacology; D000068756:Valsartan
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D057912:Angiotensin II Type 2 Receptor Blockers; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007093:Imidazoles; D007328:Insulin; D011725:Pyridines; D044140:Receptor, Angiotensin, Type 1; D044139:Receptor, Angiotensin, Type 2; D013777:Tetrazoles; D000804:Angiotensin II; C073402:PD 123319; D019377:12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; D000068756:Valsartan; D014633:Valine
references.citation: Diabetologia. 2002 Jan;45(1):125-33
references.pmid: 11845232
references.citation: Am J Physiol Renal Physiol. 2002 Nov;283(5):F985-94
references.pmid: 12372774
references.citation: Curr Opin Nephrol Hypertens. 1997 Mar;6(2):111-8
references.pmid: 9146971
references.citation: J Am Soc Nephrol. 2008 Mar;19(3):559-69
references.pmid: 18235084
references.citation: Hypertension. 2005 Jan;45(1):133-7
references.pmid: 15534073
references.citation: J Cell Physiol. 1996 Nov;169(2):391-400
references.pmid: 8908207
references.citation: Prostaglandins Other Lipid Mediat. 1998 Jan;55(1):3-25
references.pmid: 9661215
references.citation: Endocrinology. 2003 Jun;144(6):2229-33
references.pmid: 12746279
references.citation: Metabolism. 1998 Mar;47(3):257-63
references.pmid: 9500559
references.citation: Am J Physiol Regul Integr Comp Physiol. 2007 Oct;293(4):R1461-7
references.pmid: 17670863
references.citation: Nephrol Dial Transplant. 1998 May;13(5):1131-42
references.pmid: 9623541
references.citation: J Clin Invest. 1988 Dec;82(6):2136-41
references.pmid: 3143746
references.citation: Kidney Int. 2001 Apr;59(4):1354-62
references.pmid: 11260396
references.citation: J Clin Invest. 1997 Jul 15;100(2):264-9
references.pmid: 9218502
references.citation: Kidney Int. 2003 Oct;64(4):1208-13
references.pmid: 12969138
references.citation: Hypertension. 1995 May;25(5):1021-4
references.pmid: 7737709
references.citation: Am J Kidney Dis. 2008 Jan;51(1 Suppl 1):S1-320
references.pmid: 18086389
references.citation: Am J Physiol Renal Physiol. 2001 Feb;280(2):F254-65
references.pmid: 11208601
references.citation: J Clin Invest. 1987 Dec;80(6):1763-9
references.pmid: 2824567
references.citation: Kidney Int. 2006 Feb;69(3):512-9
references.pmid: 16514433
references.citation: Hypertension. 1994 Jan;23(1 Suppl):I142-7
references.pmid: 8282345
references.citation: Diabetologia. 1996 Mar;39(3):275-80
references.pmid: 8721772
references.citation: Clin Exp Pharmacol Physiol. 1992 May;19(5):343-7
references.pmid: 1325883
references.citation: J Hypertens. 2004 Aug;22(8):1571-7
references.pmid: 15257181
references.citation: Clin Exp Pharmacol Physiol. 2002 Jan-Feb;29(1-2):127-31
references.pmid: 11906471
references.citation: Semin Nephrol. 2004 Mar;24(2):93-100
references.pmid: 15017521
references.citation: Am J Physiol. 1993 Oct;265(4 Pt 2):F477-86
references.pmid: 8238377
references.citation: N Engl J Med. 2001 Sep 20;345(12):851-60
references.pmid: 11565517
references.citation: Am J Physiol. 1991 Aug;261(2 Pt 2):H451-6
references.pmid: 1908641
references.citation: Kidney Int. 1998 Mar;53(3):540-7
references.pmid: 9507197
references.citation: Am J Physiol. 1992 Sep;263(3 Pt 2):F436-42
references.pmid: 1415572
references.citation: Hypertension. 2000 May;35(5):1074-7
references.pmid: 10818067
references.citation: Diabetes. 1999 Nov;48(11):2229-39
references.pmid: 10535459
references.citation: N Engl J Med. 2001 Sep 20;345(12):870-8
references.pmid: 11565519
references.citation: J Clin Invest. 1999 Jun;103(11):1597-604
references.pmid: 10359569
references.citation: J Clin Invest. 1996 Apr 15;97(8):1978-82
references.pmid: 8621783
references.citation: J Hypertens. 2002 Aug;20(8):1615-24
references.pmid: 12172324
references.citation: N Engl J Med. 2001 Sep 20;345(12):861-9
references.pmid: 11565518
references.citation: J Clin Endocrinol Metab. 1996 May;81(5):1940-5
references.pmid: 8626861
references.citation: Biochem Biophys Res Commun. 1983 Apr 15;112(1):242-9
references.pmid: 6838610
references.citation: J Lipid Res. 2003 Dec;44(12):2391-9
references.pmid: 12951362
references.citation: Hypertension. 2002 Jan;39(1):129-34
references.pmid: 11799091
references.citation: J Am Soc Nephrol. 2005 Feb;16(2):352-62
references.pmid: 15615821
references.citation: Am J Physiol. 1990 Dec;259(6 Pt 2):H1774-80
references.pmid: 2124426
references.citation: Diabetes. 1996 Apr;45(4):522-30
references.pmid: 8603776
references.citation: J Am Soc Nephrol. 1999 Feb;10(2):245-55
references.pmid: 10215323
references.citation: J Clin Invest. 1993 Sep;92(3):1366-72
references.pmid: 7690779
references.citation: Blood. 2000 Apr 1;95(7):2304-11
references.pmid: 10733500
references.citation: Endocrine. 2002 Aug;18(3):295-301
references.pmid: 12450322
references.citation: J Clin Invest. 1985 Feb;75(2):404-12
references.pmid: 3156147
references.citation: J Clin Invest. 1994 Feb;93(2):536-42
references.pmid: 8113392
references.citation: Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):4947-51
references.pmid: 8506339